Menu
Lawmakers in May devoted close attention to the role that pharmacy benefits managers (PBMs) play in our health care system. PBMs are middlemen that create …
Pfizer Inc. today announced their Phase 3 BASIS clinical trial evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. …
On May 11, 2023, the U.S. Food and Drug Administration released final guidance providing recommendations for evaluating blood and plasma donor eligibility using individual risk-based questions. …
Recently Novo Nordisk received a Complete Response Letter from the Food and Drug Administration for concizumab. Concizumab was submitted for regulatory approval in the U.S. …
Protections for people who rely on copay assistance have been a top priority for HFA and many other patient groups for several years. That effort …
Experienced executive brings outcome-driven leadership to the national nonprofit patient advocacy group. WASHINGTON, DC, April 12, 2023 – The Board of Directors of Hemophilia Federation …
Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia Paris – April 4, 2023 – Two studies, published in The …
States can resume Medicaid terminations in April, but most are holding back The U.S. Department of Health and Human Services (HHS) has notified state Medicaid …
For over three decades, March has been designated “Bleeding Disorders Awareness Month.” HFA and member organizations across the country mark the occasion with monthlong education …
SAN RAFAEL, Calif., March 6, 2023 — BioMarin Pharmaceutical Inc., a global biotechnology company dedicated to transforming lives through genetic discovery, announced that it received notice …
The long-heralded Medicaid “unwinding” has begun. As previously reported, state Medicaid programs have, since the start of the COVID-19 pandemic, operated under a law that prohibited …
Source: Sanofi Press Release Sanofi announces that the U.S. Food and Drug Administration approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-vWF-XTEN Fusion Protein-ehtl], previously known as efanesoctocog …
Dear Addy, I recently attended an event and learned about submitting issues with my insurance to HFA’s Project CALLS. I have an insurance issue, however, …
This Black History Month, HFA asks our community to think back on the family members they’ve loved and the moments they created. We ask our …
HFA reports on a particularly concerning insurance problem unfolding in Tennessee, and how HFA is responding; news on Medicaid eligibility reviews; changes in blood donation policy; and much more.